比较脑脊液p-tau181、p-tau217与p-tau231检测的临床效用与诊断性能
本研究基于瑞典BioFINDER-2队列629名参与者,比较了脑脊液p-tau181、p-tau217和p-tau231对阿尔茨海默病的诊断准确性及其与Aβ和tau-PET的关联。结果显示p-tau217Lilly具有最大的动态范围、更强的PET相关性以及更高的诊断准确性。不同p-tau181检测方法间结果差异提示抗tau抗体对生物标志物性能的重要性。
要点
- 脑脊液p-tau217Lilly在区分AD痴呆与非AD疾病方面AUC达0.98,优于其他p-tau变体。
- p-tau217Lilly与Aβ-PET和tau-PET的相关性最强(p < 0.0001)。
- 不同p-tau181检测方法性能差异显著,提示抗体选择影响生物标志物表现。
核心结论
- 脑脊液p-tau217Lilly在AD诊断流程中可能比其他纳入的p-tau检测更有用。
- p-tau181不同检测方法间结果差异凸显抗tau抗体对生物标志物性能的重要性。
研究设计与样本
- 研究纳入瑞典BioFINDER-2队列共629名参与者,包括认知正常334人、Aβ阳性轻度认知障碍84人、AD痴呆119人和非AD疾病92人。
- 同时测量p-tau181(Lilly、Innotest和Elecsys检测)、p-tau217Lilly和p-tau231。
主要发现
- 所有p-tau变体在AD连续谱中均升高,p-tau217Lilly动态范围最大(AD痴呆 vs 非AD升高13倍,其他变体为1.9-5.4倍)。
- p-tau217Lilly与Aβ-PET和tau-PET相关性更强(p < 0.0001)。
- p-tau217Lilly区分AD痴呆与非AD的AUC为0.98,高于其他变体的0.88(p < 0.0001)至0.96(p < 0.05)。
- p-tau217Lilly识别Aβ-PET阳性的AUC为0.86,高于其他变体的0.74(p < 0.0001)和0.83(p < 0.001);识别tau-PET阳性的AUC为0.94,高于其他变体的0.80-0.92(p < 0.0001)。
- p-tau181Lilly通常优于其他p-tau181检测(如AD痴呆 vs 非AD,AUC 0.96 vs p-tau181Innotest 0.88和p-tau181Elecsys 0.89;p < 0.0001)。
关键数值与推荐
- p-tau217Lilly区分AD痴呆与非AD的AUC为0.98,其他p-tau变体为0.88(p < 0.0001)至0.96(p < 0.05)。
- p-tau217Lilly识别Aβ-PET阳性的AUC为0.86,其他变体为0.74(p < 0.0001)和0.83(p < 0.001)。
- p-tau217Lilly识别tau-PET阳性的AUC为0.94,其他变体为0.80-0.92(p < 0.0001)。
- p-tau181Lilly区分AD痴呆与非AD的AUC为0.96,p-tau181Innotest为0.88,p-tau181Elecsys为0.89(p < 0.0001)。
临床怎么用
- 在AD的脑脊液生物标志物检查中,p-tau217Lilly可能提供更高的诊断准确性。
- 选择p-tau181检测时需注意不同检测方法性能差异,抗体来源影响结果解读。
局限性
- 研究基于瑞典BioFINDER-2单队列,外部推广性需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Phosphorylated tau (p-tau) in CSF is considered an important biomarker in Alzheimer disease (AD) and has been incorporated in recent diagnostic criteria. Several variants exist, including p-tau at threonines 181 (p-tau181), 217 (p-tau217), and 231 (p-tau231). However, no studies have compared their diagnostic performance or association to β-amyloid (Aβ) and tau-PET. Understanding which p-tau variant to use remains an important yet answered question. We aimed to compare the diagnostic accuracy of p-tau181, p-tau217, and p-tau231 in CSF for AD and their association with Aβ and tau-PET. METHODS: A total of 629 participants in the Swedish BioFINDER-2 study were included (cognitively unimpaired, n = 334; Aβ-positive mild cognitive impairment, n = 84; AD dementia, n = 119; and non-AD disorders, n = 92). In addition to p-tau181 and p-tau217 measured using assays with the same detector antibodies from Eli Lilly (p-tau181Lilly, p-tau217Lilly) and p-tau231, we also included p-tau181 measurements from 2 commonly used assays (Innotest and Elecsys). RESULTS: Although all p-tau variants increased across the AD continuum, p-tau217Lilly showed the greatest dynamic range (13-fold increase vs 1.9-5.4-fold increase for other p-tau variants for AD dementia vs non-AD). P-Tau217Lilly showed stronger correlations with Aβ- and tau-PET (p < 0.0001). P-Tau217Lilly exhibited higher accuracy than other p-tau variants for separating AD dementia from non-AD (area under the curve [AUC], 0.98 vs 0.88 [p < 0.0001] - 0.96 [p < 0.05]) and for identifying Aβ-PET (AUC, 0.86 vs 0.74 [p < 0.0001] and 0.83 [p < 0.001]) and tau-PET positivity (AUC, 0.94 vs 0.80-0.92, p < 0.0001). Finally, p-Tau181Lilly generally performed better than the other p-tau181 assays (e.g., AD dementia vs non-AD, AUC, 0.96 vs 0.88 [p-tau181Innotest] and 0.89 [p-tau181Elecsys]; p < 0.0001). DISCUSSION: CSF p-tau217Lilly seems to be more useful than other included p-tau assays in the workup of AD. Varied results across p-tau181 assays highlights the importance of anti-tau antibodies for biomarker performance. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that p-tau217 provides higher diagnostic accuracy for diagnosis of AD dementia than p-tau181 or p-tau231.
引用
- Leuzy A, Janelidze S, Mattsson-Carlgren N, et al. Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. Neurology. 2021. PMID: 34493616. doi:10.1212/WNL.0000000000012727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。